Kymera Therapeutics, Inc.
KYMR
$30.02
$0.270.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.10M | 7.39M | 3.74M | 25.65M | 10.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.10M | 7.39M | 3.74M | 25.65M | 10.29M |
| Cost of Revenue | 80.26M | 71.82M | 60.41M | 59.20M | 48.82M |
| Gross Profit | -58.16M | -64.42M | -56.67M | -33.55M | -38.53M |
| SG&A Expenses | 16.27M | 16.33M | 15.46M | 17.37M | 14.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.53M | 88.15M | 75.87M | 76.58M | 63.19M |
| Operating Income | -74.43M | -80.76M | -72.12M | -50.93M | -52.91M |
| Income Before Tax | -65.58M | -70.75M | -62.49M | -42.06M | -48.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.58M | -70.75M | -62.49M | -42.06M | -48.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.58M | -70.75M | -62.49M | -42.06M | -48.56M |
| EBIT | -74.43M | -80.76M | -72.12M | -50.93M | -52.91M |
| EBITDA | -72.38M | -80.17M | -70.14M | -48.99M | -51.45M |
| EPS Basic | -0.82 | -0.88 | -0.82 | -0.58 | -0.69 |
| Normalized Basic EPS | -0.51 | -0.55 | -0.51 | -0.36 | -0.39 |
| EPS Diluted | -0.82 | -0.88 | -0.82 | -0.58 | -0.69 |
| Normalized Diluted EPS | -0.51 | -0.55 | -0.51 | -0.36 | -0.39 |
| Average Basic Shares Outstanding | 80.15M | 79.99M | 76.13M | 73.06M | 70.77M |
| Average Diluted Shares Outstanding | 80.15M | 79.99M | 76.13M | 73.06M | 70.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |